Rep. Lloyd Doggett (D-TX) recently introduced the Medicare Negotiation and Competitive Licensing Act of 2018. Lest the title confuse you, by “competitive licensing” Rep. Doggett means compulsory licensing anytime a company declines to sell their drug for whatever price the Secretary of Health and Human Services cares to offer during “Medicare negotiations” where the government holds all the cards. Past attempts to impose artificial “reasonable pricing” requirements on developers of government supported inventions did not result in cheaper drugs. A study titled Compulsory Licensing Often Did Not Produce Lower Prices For Antiretrovirals Compared to International Procurement found that resulting drug prices were often higher than they would have been under a more cooperative approach.
The post Compulsory Licensing for Medicare Drugs– Another Bad Idea from Capitol Hill appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- The Return of a Mandate on Patent Infringement Precludes Further Consideration of Issues Actually Decided
- CAFC Affirms TTAB Ruling that FIREBALL is Not Generic but Competitor’s Mark Won’t Confuse
- John Squires Becomes Official Nominee to Head USPTO
- Other Barks & Bites for Friday, March 7: Lashify Wins ITC Appeal on Economic Prong Analysis; CAFC Says Apple Did Not Violate Discovery Obligations at PTAB; and ParkerVision Files Reply Brief on Rule 36 Appeal at SCOTUS
- Rio Tinto is Seeking an IP Counsel Innovation & Technology